BCIQ Profiles

Company Profile Report
0201 Horizon Viela
BioCentury & Getty Images


Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B

Three-year path as stand-alone company culminates in takeout

Viela’s three-year journey as an independent company has culminated in a takeout.

Feb 1, 2021 | 11:14 PM GMT

Horizon’s $3 billion-plus buyout of Viela caps the biotech’s three-year journey as an independent company spun out from AstraZeneca’s MedImmune unit, with an IPO and a drug approval along the path to value creation.

It will be up to Horizon Therapeutics plc (NASDAQ:HZNP)

Read the full 849 word article

How to gain access

Continue reading with a
two-week free trial.